



MEDIPOST



Life-Changing **INNOVATIONS**

The Future of Biotechnology, **MEDIPOST**

Investor Relations

Life-Changing **INNOVATIONS**

Table of Contents

- Overview
- Drug Development
- CGT CDMO
- Cord Blood Bank
- Timeline



— Overview

Life-Changing
INNOVATIONS

The Future of Biotechnology, **MEDIPOST**

MEDIPOST

Stem-Cell Therapy



1st Generation Stem Cell Therapy

- Cartistem / knee osteoarthritis
- Pneumostem / bronchopulmonary dysplasia (BPD)

2nd Generation Stem Cell Therapy

- SMUP-IA-01 / knee osteoarthritis
- #### Advanced Regenerative Therapies
- Anti-aging / regenerative
- #### Umbilical Cord Blood-derived Immune Cell Therapy
- Under development by subsidiary Immunique
 - Utilizes immunomodulatory T-cells

Cord Blood Banking



Domestic #1 Market Share
9th Largest Cord Blood Bank Globally

Accumulated number of cord blood storage:
313,484 units
 (As of end-2024)

Domestic Market Share (trailing 10 years): ~70%

CGT CDMO



OmniaBio

- CGT CDMO (established in 2021)
- Located in Toronto, Canada
- State of the art production facilities and process development capabilities
- Retains a network of CGT development companies within N. America

Domestic CGT CDMO

- CGT CDMO total solution services
- Provision of global services (in conjunction with OmniaBio)

Health Supplements



Provision of nutrition solutions under the Movita brand

- Specialized products for both pregnant women and women
- Customized products with varying ingredients and features
- Sold through both hospitals and online channels



—
Drug Development


Life-Changing
INNOVATIONS

The Future of Biotechnology, **MEDIPOST**

Stem Cell Therapy Development Pipeline

Indication	Therapy	Clinical Trial Location	Pre-Clinical	Phase I	Phase II	Phase III	BLA	Details
 <p>Knee Osteoarthritis</p>	CARTISTEM®	S. Korea	[Progress bar: Pre-Clinical, Phase I, Phase II, Phase III]					Korea BLA in 2012
		USA	[Progress bar: Pre-Clinical, Phase I (red), Phase II, Phase III]					Phase 1/2a completed Phase 2 omitted based on Korea clinical trial data & domestic post-commercialization data Phase 3 IND approval in 1H26
		Japan	[Progress bar: Pre-Clinical, Phase I (red), Phase II, Phase III]					Phase 3 completed Phase 1, Phase 2 omitted based on Korea clinical trial data & domestic post-commercialization data
	SMUP-IA-01	S. Korea	[Progress bar: Pre-Clinical, Phase I, Phase II]					Phase 2 completed Phase 3 preparations ongoing
		USA	[Progress bar: Pre-Clinical, Phase I (red), Phase II]					Pre-IND meeting completed Phase 1 omitted based on Korea clinical trial data
	 <p>Bronchopulmonary Dysplasia (BPD)</p>	PNEUMOSTEM®	S. Korea	[Progress bar: Pre-Clinical, Phase I, Phase II]				
USA			[Progress bar: Pre-Clinical, Phase I, Phase II]					Phase ½ completed US / EU orphan drug designation US Fast Track designation

Over 270mm knee osteoarthritis patients in the 8 major markets
(US, Japan, China, UK, France, Germany, Spain, Italy)




* 2023년 기준

Osteoarthritis

Pain, Stiffness, Movement restrictions → Clinical symptom

CARTISTEM® Treatment

Cartilage repair → Improvement of clinical symptom



Matrix metalloproteinases	Chondrocyte
Inflammation	Enzyme inhibition molecules
hUCB-MSCs	Anti-inflammation molecules
Activated hUCB-MSCs	Chondrogenic factor

Research results

- Inhibition of cartilage matrix degradation : To be published
- Promotion of cartilage regeneration : Jeong et al(2013) Stem Cells, 31(10):2136-2148, Park et al(2015) J Orthop Res. 33(11):1580-1586, Ha et al(2015) Stem Cells Transl Med 4(9):1044-1051, Park et al(2016) PLoS One 11(11):e0165446
- Modulation of inflammation : To be published




Figure 4 Second-look arthroscopic findings. A: Cartilage lesions classified as International Cartilage Repair Society (ICRS) grade IV in the medial femoral condyle (MFC) (arrow) and tibial plateau in a 61-year-old female patient; B: Cartilage was regenerated to ICRS grade I (arrow) via second-look arthroscopy, performed 13 mo after the initial operation; C: A cartilage lesion classified as ICRS grade IV in the MFC (arrow) of a 52-year-old male patient; D: Cartilage was regenerated to ICRS grade II (arrow) via second-look arthroscopy, performed 22 mo after the initial operation; E: A cartilage lesion of ICRS grade IV in the MFC (arrow) of a 68-year-old female patient; F: Cartilage was regenerated to ICRS grade III (arrow) via second-look arthroscopy, performed 16 mo after the initial operation.

Reference: Song J.S. et al. (2020) World J Stem Cells 2020 June 26; 12(6): 514-526

Cartistem Japan Phase 3 details

- Targeting the Japanese knee osteoarthritis market based on the safety and efficacy demonstrated through our domestic clinical trial results and post-commercialization data
- **Omitted both Phase 1 and Phase 2 studies** due to our exceptional domestic clinical trial results
- Phase 3 approval (Feb 2021), initiation (Mar 2022), first patient dosed (early 2023), LPI Nov. 2024, **LPO completed in Nov. 2025**

		Phase 3
Purpose		<ul style="list-style-type: none"> ▪ Evaluation of efficacy and safety of Cartistem (EVA-001) in patients with ICRS grade 3~4, K&L grade 2~3 knee osteoarthritis
Study Design		<ul style="list-style-type: none"> ▪ Randomized, active control, open label
Number of Patients		<ul style="list-style-type: none"> ▪ Total of 130 patients (treatment group 65 patients/active control group 65 patients)
Group Setting		<ul style="list-style-type: none"> ▪ Treatment Group: Cartistem (EVA-001) ▪ Active Control: Sodium Hyaluronate (injection)
Endpoints	Primary Endpoint	<ul style="list-style-type: none"> ▪ Change in WOMAC scale, 52 weeks after surgery ▪ Improvement in ICRS Grade 1, 52 weeks after surgery
	Secondary Endpoint	<ul style="list-style-type: none"> ▪ Pain and functionality evaluation (WOMAC , KOOS, IKD, etc.) ▪ Structural improvement evaluation (ICRS , biopsy, MRI, X-ray, etc.)
Current Status		<ul style="list-style-type: none"> ▪ CTN approval (Feb. 2021), clinical trial on-going


Five-year long term follow up data of Cartistem's domestic Phase 3 clinical study; long-term efficacy confirmed



- Cartilage regeneration / prevention of cartilage degradation demonstrated
- Over 600 cases reported through post-marketing surveillance (Mar, 2017)

Phase 3 5-year Follow Up Data

· **5-year follow-up results** showed **statistically significant improvements** in terms of 100mm VAS¹⁾, IKDC score²⁾ and WOMAC³⁾ scale, when compared to the active control (microfracture)



100mm VAS¹⁾: Measure of pain intensity, used to record patients' pain progression




IKDC Score²⁾: Standardized documentation system for knee conditions (measures 7 symptom items, 2 function items, 2 sports activity items)

WOMAC³⁾: Standard questionnaire used to evaluate the condition of patients with knee osteoarthritis (measures 5 pain items, 2 stiffness items, 17 functional limitations items)

Cartilage regeneration confirmed through Cartistem's domestic Phase 3 study



- Phase 3 results confirmed cartilage regeneration in 98% of treated patients (K&L 2~3, ICRS grade 4)
- Approx. ~70% of the treatment group patients showed improvements exceeding 2 ICRS grades
- Applicable to all age groups and cartilage defect sizes between 2cm² ~ 9cm²
- Confirmed the **regeneration of hyaline cartilage**



■ CARTISTEM® ■ Microfracture


Absence of SOC (standard of care) treatments for moderate KOA patients globally

Type	Oral / Injection Treatments	N/A	Surgical Treatments		Surgical Treatment
Severity	Mild	Moderate	Severe		Moderate
Treatment	NSAIDS, Steroids, Hyaluronic Acid	NO STANDARD OF CARE AVAILABLE = (HIGH UNMET MEDICAL NEEDS)	Total / Partial Knee Arthroplasty		CARTISTEM
Indication	Pain Relief		Knee Osteoarthritis		Knee Osteoarthritis
Purpose	Pain Relief		Artificial Joint Replacement		Cartilage Regeneration, Pain & Function Improvements
Treatable Damage Size	N/A		4~20cm ²		2~9cm ²
Target Age Group	No age limit		Over 65 years old		18~80
Pros	Accessibility		Proven Track Record		Cartilage Regeneration
Cons	Short term relief		Drastic lifestyle changes		High Treatment Costs


Conducting RWE (Real World Evidence) study for CARTISTEM® in Korea to further support regulatory approvals abroad


Collection of long-term data for ~500 patients treated with Cartistem across 11 sites

-> Data for ~300 patients compiled as of Oct. 2025




Japan Commercialization Timeline





M E D I P O S T




TEIKOKU SEIYAKU CO.,LTD.

- KRW11.7bn in upfront payment, KRW14.7bn in short-term regulatory-based milestone, undisclosed long-term sales-based milestones
- Exclusive Japan commercialization license, 10 year contract period
- MEDIPOST to retain manufacturing rights, to supply drug substance from Korea and drug product to be manufactured locally within Japan
- Teikoku Seiyaku to deploy / manage on the scale of 100 dedicated orthopedic sales, marketing & medical science liaison specialists focusing on the commercialization of CARTISTEM®
- In talks with potential partners regarding business development opportunities in the US, China & other regions



Global Pharmaceutical Market (2023 Sales-based)




* Excludes China & Japan

Osteoarthritis

Pain, Stiffness, Movement restrictions → Clinical symptom


SMUP-IA-01 Treatment

Cartilage repair → Improvement of clinical symptom





- | | |
|---------------------------|-----------------------------|
| Matrix metalloproteinases | Chondrocyte |
| Inflammation | Enzyme inhibition molecules |
| hUCB-MSCs | Anti-inflammation molecules |
| Activated hUCB-MSCs | Chondrogenic factor |


Safety and efficacy confirmed





- 12x K&L grade 2~3 patients (low dose 3x, mid dose 3x, high dose 6x)
- Average age 69 / female 11x + male 1x / K&L G3 11x + G2 1x
- 6 month observation after the administration of a single injection to the intra-articular cavity
- No serious adverse events or adverse drug reactions
- **WOMAC -15.33 ± 5.77 / 100mm VAS -39.67 ± 10.00 / IKDC 19.17 ± 5.12 improvement**



Safety and efficacy confirmed



- 94x K&L grade 2~3 patients (low dose 31x, mid dose 33x, active control 30x)
- Change in WOMAC scale, 52 weeks after administration (single intra-articular injection)
- No serious adverse events or adverse drug reactions
- Comparison of changes in total WOMAC score across the 3 cohorts **showed no statistically significant difference**
 - Low Dose -17.61±2.35,
 - Mid Dose -14.69±2.32,
 - Active Control -16.20±2.39 improvement
- Comparison of changes in both 100mm VAS & IKDC score across the 3 cohorts **showed no statistically significant differences**



—
CGT CDMO



Life-Changing
INNOVATIONS

The Future of Biotechnology, **MEDIPOST**

Entered into the CGT CDMO business given the high synergy with our core competencies and to secure a strategic production base within N. America

- Secured a strategic production base in N. America in preparation for the clinical development and commercialization of both Cartistem and SMUP-IA-01
- Establishment of a stable growth foundation by entering into a new business which can be synergized with our cell selection & culture technologies
- Entrance into the world's largest pharmaceutical market (N. America: ~40% of the global pharmaceutical market)

Acquisition of a proven CGT CDMO with superior production facilities and process development capabilities

CCRM

(Center for Commercialization of Regenerative Medicine)



- Center for Commercialization of Regenerative Medicine (Government sponsored non-profit research organization established in 2011)
- Located in Toronto, Canada
 - N. America east coast Bio Cluster – Boston, Philadelphia, Washington, Toronto
 - Extensive healthcare research / exceptional talent
- **CGT Incubator / ecosystem builder**
- Industry-leading CGT process development capabilities & production infrastructure (in partnership with Cytiva)



OmniaBio



- CGT CDMO (Established in 2021)
- Located in Toronto, Canada
- Superior production facilities and process development capabilities
 - 11,200m² (PD & QC Laboratories + GMP)
 - Autologous / allogeneic stem cell therapies, iPSC, gene modified cell therapies, etc.
- **Retains a broad network of CGT development companies within the N. America region**



Cord Blood Bank

Life-Changing
INNOVATIONS

The Future of Biotechnology, **MEDIPOST**



Korea's Most-Trusted Cord Blood Bank CELLTREE®



South Korea's #1 Cord Blood Bank

Cord blood storage exceeding 300,000 units

World's Top 10 Cord Blood Banks by Inventory and Industry Consolidation

Inventory Units	Bank Name	Region	Multi-Lab?	Multi-Nation?	Business Model
875000	CBR, a California Cryobank Co.	USA+	yes	yes	private
882219	Global Cord Blood Corp	China	yes	no	private/public
470000	Viacord	USA	no	no	private
380000	Cardlife Group	Asia Pacific	yes	yes	private/public
350000	FamCard Group	Europe	yes	yes	private/public
350000	Crye-Save	Europe+	yes	yes	private
300000	VivoCell (Union Stem Cell)	China	yes	no	private/public
300000	LifeCell	India+	yes	yes	community
242028	Medipost (CellTree)	South Korea	no	no	private/public
215000	Viva 34	Europe	no	yes	private/public



World's Top 9 Cord Blood Banks

Bank Name	Region
Medipost (CellTree)	South Korea
CBR, a California Cryobank Co.	USA+
Global Cord Blood Corp	China
Viacord	USA

[Parent's Guide to Cord Blood Foundation : 미국 내 유일한 기준 및 가족 제대혈은행의 데이터베이스 보유 기관]



Based on cutting-edge stem cell technology, CELLTREE® boasts exceptional expertise and robust know-how relating to cord blood handling, cell preparation and cryopreservation.

1st CELLTREE® **122,738 Units**

2nd Cord Blood Banks **37,685 Units**

* Source: Disclosures from listed companies operating cord blood banks (cumulative 2014~2023)

—
Timeline



Life-Changing
INNOVATIONS

The Future of Biotechnology, **MEDIPOST**

2026

2027




- Cartistem Japan BLA Submission
- Cartistem US P3 Protocol Release
- JPMorgan Healthcare Conference 2026 Attendance
- Cartistem US Phase 3 Clinical Trial Initiation
- Cell & Gene Meeting on the Mesa Attendance
- Cartistem US P3 1st Patient In
- SMUP-IA-01 Domestic P3 IND Submission
- BIO USA Attendance
- Cartistem Japan Phase 3 Topline Results
- International Society for Cell & Gene Therapy Attendance
- Real World Evidence Study Results

- JPMorgan Healthcare Conference 2027 Attendance
- Cell & Gene Meeting on the Mesa Attendance
- Cartistem Japan BLA Approval
- BIO USA Attendance
- International Society of Cell & Gene Therapy Attendance
- Japan Cartistem Pricing Talks

Revenue Breakdown by Division

Unit: KRW mn

Unit: # of Vials



(Unit: KRW MM)	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	28,190	29,429	29,715	35,089	28,653	42,250	44,383	45,803	48,627	54,915	61,394	69,707	74,113
Cord Blood Bank	22,433	21,876	22,077	23,971	15,884	19,464	21,009	22,237	21,031	25,773	29,511	32,694	39,175
Cell Therapy	727	1,994	2,793	4,125	5,638	10,030	13,652	15,941	16,437	17,233	19,460	21,740	20,318
Health Supplements	4,682	4,925	4,048	4,201	4,251	5,915	4,249	5,488	7,470	9,707	9,881	9,552	8,852
Misc.	348	634	797	2,792	2,880	6,841	5,473	2,137	3,689	2,203	2,542	5,721	5,768

Life-Changing **INNOVATIONS**

The Future of Biotechnology, **MEDIPOST**

